HVPG also significantly decreased from 13.9±5.6 mmHg to 12.3±5.2 mmHg (p<0.0001 vs. baseline). Average reduction was -10.7±17.9%; HVPG decreased ≥10% in 42% and ≥20% in 24% of pts. HVPG decreased below 10 mmHg in 4 patients, all with weight reduction ≥ 5%. Pts showing weight reduction ≥10% had a greater decrease in HVPG vs. pts with weight reduction <10% (-23.7±19.9% vs. -8.2±16.6%p=0.024). LDK378 price Both weight and HVPG decrease were less marked in pts with diabetes. Results were similar across etiologies of cirrhosis, clinically significant portal hypertension and EV, treatment with NSBB, history of variceal bleeding and study Center. No

episodes of clinical decompensation occurred during the study; Child and MELD scores did not change. Weight loss was maintained after 6 months (6 mo weight: 84.8 Kg vs. 85.7 Kg at 16-wk, p=0.136). CONCLUSIONS. In obese patients with cirrhosis and portal hypertension, lifestyle intervention by means of diet and moderate exercise for 16 weeks was safe, reduced body weight and effectively reduced HVPG. HVPG decreased by ≥10% in ∼40% of cases and this occurred also in patients on NSBB therapy, suggesting that weight reduction by lifestyle changes NVP-AUY922 should be recommended in this population. (Clinical

Trials.gov identifier NCT 01409356). Disclosures: Juan Carlos Garcia-Pagan – Grant/Research Support: GORE Jaime Bosch – Consulting: Falk, Gilead Science, Norgine, ONO-USA, Intercept pharma, Exalenz, Almirall, Conatus; Grant/Research Support: Gore The following people have nothing to disclose: Annalisa Berzigotti, Agustin Albil-los, Càndid Villanueva, Joan Genescà, Alba Ardevol, Salvador Augustin, Jose Luis Calleja, Rafael Bañares, Francisco Mesonero The University of California, San Francisco group has shown excellent post-LT outcome for selected patients

following successful HCC down-staging to Milan criteria. Eligibility criteria in this down-staging protocol include 1 lesion >5 cm and ≤ 8 cm, 2-3 lesions at least one >3 cm but ≤ 5 cm and total tumor diameter ≤ 8 cm, or 4-5 tumors ≤ 3 cm with total tumor diameter ≤ 8 cm. A minimum observation period of 3 months after down-staging was required before LT. This protocol has since been adopted by Region 5 although post-LT outcomes have not yet been reported from other Region 5 centers. In this mul-ticenter study, we aimed to assess post-LT and intention to treat outcomes under this uniform down-staging this website protocol. Patients from three Region 5 centers (n=187) were enrolled from March 2002 to December 2012. Median pre-treatment alpha-feto-protein (AFP) was 24 ng/mL (IQR 8-154) and median Child-Pugh score was 7 (IQR 5-8). Forty-eight patients (26%) had a single down-staging treatment and 49 (26%) received >3 treatments. LT was performed after successful down-staging in 109 patients (58%). Dropout occurred in 68 patients (36%), mostly from tumor progression or death; 10 were still awaiting LT. Median time from first down-staging procedure to LT or dropout was 12.6 and 7.